CorMedix, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Investors with losses are encouraged to contact the firm before September 20, 2021; click here to submit trade information

LOS ANGELES, July 27, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of CorMedix, Inc. (NASDAQ: CRMD) investors that acquired shares between July 8, 2020 and May 13, 2021. Investors have until September 20, 2021 to seek an active role in this litigation.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

It is alleged in this complaint that CorMedix made misleading and false statements to the market. CorMedix suffered from deficiencies in relation to DefenCath’s manufacturing process. Based on these deficiencies, it was unlikely that the FDA would approve CorMedix’ NDA for DefenCath. The Company downplayed the extent of these manufacturing problems in its public statements. CorMedix’ public statements were materially misleading and false throughout the class period, based on these facts. Investors suffered damages when the market learned the truth about CorMedix.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 20, 2021.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.